Subsidiary will provide a web platform for personal genetic information and analysis starting in April.

GATC Biotech has formed a subsidiary company, LifeCode, as a web-based  information service for the storage and utilization of biological and medical data from the analysis of genetic and protein codes in the EU.

LifeCode says that it plans to start providing its information services during April. With this spin-off, GATC is set to focus on sequencing services.

Major advances in analytical methods are making it easier to examine portions of the genetic code, its regulation, and to find out which proteins occur frequently. Scientists are working on defining the risks and genetic interrelationships that play a role in the development of certain diseases.

LifeCode will satisfy the need for a method to update this complex information in real time, according to GATC. The data will be made available on a reliable and lucid platform for medical consultation, guaranteeing a high level of security, the company adds. LifeCode will provide a platform with which each person can record and manage his or her own biological code.

LifeCode stresses, though, that results from genetic examinations must not be confused with medical diagnoses. Hence, the company will focus on preparing and presenting information from a customer’s genetic profile into a scientific and medical context. The firm will identify findings as not certain and hopes to thus prevent unreliable conclusions.

“One major concern of LifeCode is to ensure that every customer is able to make an informed decision with respect to biological tests and that no examinations are undertaken under any incorrect understanding, without explanation, and without the customer’s informed agreement,” asserts Peter Pohl, CEO of GATC Biotech and the newly founded LifeCode.

“That means that when, for example, we determine a person’s lineage, we as service providers even in the field of nonmedical genetic diagnosis must comply with the same strict requirements as those that apply in the case of medical genetic diagnosis.”

Previous articleOphthotech Secures Licenses for Ophthalmic Uses of mAb from Biogen Idec and PDL
Next articleNicOx to Receive €3M in Funding through One-Year Extension of Opthamology Deal with Pfizer